The Neuro Consortium was a collaboration with researchers in the neurogenomics community. The consortium contributed content in a high-density neuro-targeted array for investigation of neurodegenerative diseases. This array combines a genome-wide backbone with over 180K expertly selected, easily accessible neurodegenerative disease markers.
The Neuro Consortium Array offers a rapid, cost-effective, high-throughput genotyping solution for fine mapping and replication of previously identified genetic variants associated with common neurodegenerative diseases. The neurodegenerative content is modular and portable as an add-on, focused content set to selected Illumina genome-wide backbone arrays.
Experts in different disease areas carefully identified markers found in known neurodegenerative disease genes. The consortium based marker selection on extensive literature review, validated research results, and in-depth database search. Content includes specific focus on the following diseases.
Neuroscience researchers are using NGS to identify variants for a new sequencing array designed for ADHD, autism, and schizophrenia studies. Variants identified through NGS and in large consortium studies will inform the construction of the CogChip.Read Interview